Farah Al Madfai1, Syed Tabish R Zaidi1, Long Chiau Ming1,2, Troy Wanandy3, Rahul P Patel1. 1. Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia. 2. School of Pharmacy, KPJ Healthcare University College, Nilai, Malaysia. 3. Department of Pharmacy, Royal Hobart Hospital, Hobart, Australia.
Abstract
BACKGROUND: Severe infections such as endocarditis and osteomyelitis require long-term treatment with parenteral antibiotics and hence prolonged hospitalisation. Continuous infusion of ceftaroline through elastomeric devices can facilitate early hospital discharge by managing parenteral antibiotics in patient's home. Therefore, the purpose of this study was to investigate the stability of ceftaroline in a commonly used elastomeric device. METHOD: A total of 24 elastomeric devices were prepared, and six elastomeric devices containing 6mg/mL of ceftaroline (three in each type of diluents) were stored at one of the following conditions: 4°C for 6 days, 25°C for 24hours, 30°C for 24hours or 35°C for 24hours. An aliquot was withdrawn before storage and at different time points. Chemical stability was measured using a stability indicating high-performance liquid chromatography, and physical stability was assessed as change in pH, colour and particle content. RESULTS: Ceftaroline, when admixed with both diluents, was stable for 144, 24 and 12hours at 4°C, 25°C and 30°C, respectively. At 35°C, ceftaroline admixed with normal saline (NS) and glucose 5% was stable for 12hours and for 6hours, respectively. No evidence of particle formation, colour change or pH change was observed throughout the study period. CONCLUSIONS: Our findings support 12 or 24hours continuous elastomeric infusion of ceftaroline-NS admixture, and bulk preparation of elastomeric pumps containing ceftaroline solution in advance. This would facilitate early hospital discharge of patients eligible for the elastomeric-based home therapy and avoid the need for patient's caregivers travelling to the hospital on a daily basis.
BACKGROUND: Severe infections such as endocarditis and osteomyelitis require long-term treatment with parenteral antibiotics and hence prolonged hospitalisation. Continuous infusion of ceftaroline through elastomeric devices can facilitate early hospital discharge by managing parenteral antibiotics in patient's home. Therefore, the purpose of this study was to investigate the stability of ceftaroline in a commonly used elastomeric device. METHOD: A total of 24 elastomeric devices were prepared, and six elastomeric devices containing 6mg/mL of ceftaroline (three in each type of diluents) were stored at one of the following conditions: 4°C for 6 days, 25°C for 24hours, 30°C for 24hours or 35°C for 24hours. An aliquot was withdrawn before storage and at different time points. Chemical stability was measured using a stability indicating high-performance liquid chromatography, and physical stability was assessed as change in pH, colour and particle content. RESULTS: Ceftaroline, when admixed with both diluents, was stable for 144, 24 and 12hours at 4°C, 25°C and 30°C, respectively. At 35°C, ceftaroline admixed with normal saline (NS) and glucose 5% was stable for 12hours and for 6hours, respectively. No evidence of particle formation, colour change or pH change was observed throughout the study period. CONCLUSIONS: Our findings support 12 or 24hours continuous elastomeric infusion of ceftaroline-NS admixture, and bulk preparation of elastomeric pumps containing ceftaroline solution in advance. This would facilitate early hospital discharge of patients eligible for the elastomeric-based home therapy and avoid the need for patient's caregivers travelling to the hospital on a daily basis.
Authors: Tony T Ho; Jose Cadena; Lindsey M Childs; Miguel Gonzalez-Velez; James S Lewis Journal: J Antimicrob Chemother Date: 2012-02-06 Impact factor: 5.790
Authors: Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2011-01-24 Impact factor: 5.191
Authors: Alan F Goodfellow; Amy O Wai; Luciana Frighetto; Carlo A Marra; Barbara M Ferreira; M Lynn Chase; Ruth E Nicol; Carole A Leong; Sally Tomlinson; Peter J Jewesson Journal: Ann Pharmacother Date: 2002-12 Impact factor: 3.154
Authors: Jane W A Vella-Brincat; Evan J Begg; Kate Gallagher; Carl M J Kirkpatrick; Mei Zhang; Chris Frampton; Stephen T Chambers Journal: J Antimicrob Chemother Date: 2004-03-10 Impact factor: 5.790
Authors: Beatriz Fernández-Rubio; Paula Del Valle-Moreno; Laura Herrera-Hidalgo; Alicia Gutiérrez-Valencia; Rafael Luque-Márquez; Luis E López-Cortés; José María Gutiérrez-Urbón; Sonia Luque-Pardos; Aurora Fernández-Polo; María V Gil-Navarro Journal: Antibiotics (Basel) Date: 2021-12-30